Wuhan Yzy Biopharma Co., Ltd.

Lijuan Fang

Pengfei Zhou

Tao Wang

Yang Liu

Jing Zhang

Liu Hu

Yongxiang Yan

Liang Zeng

Yu Zhang

Mi Huang

Kesuo Fan

The present disclosure relates to a modified Fc fragment, antibodies containing the same and the use thereof. The Fc fragment is derived from human IgG1, and the constant region CH2 domain of the Fc fragment contains multiple substitutions. Such substitution can significantly reduce the binding ability of Fc fragment to Fcγ receptors (FcγR), and reduce the non-specific activation of T cells by antibodies (such as anti-CD3 antibodies).

Modified Fc fragment, antibody comprising same, and application thereof

Provided in the present application is a humanized and multifunctional CD3 antibody; a heavy chain variable region of the CD3 antibody comprised herein contains the amino acid sequence of any one of SEQ ID NOs: 1-3 or a variant sequence thereof; and a light chain variable region thereof contains the amino acid sequence of any one of SEQ ID NOs: 26-28 or a variant sequence thereof. Further provided in the present application is a multifunctional antibody comprising (a) a light chain-heavy chain pair that has specificity for tumor cells or microorganisms; and (b) a fusion peptide that comprises a single-chain variable fragment and an Fc fragment having a CH2 domain and/or a CH3 domain, the fusion peptide having specificity for immune cells. The antibodies provided in the present application have improved biological activity, thermal stability and/or acid resistance.

CD3 antigen binding fragment and application thereof

Provided are compositions comprising a MSBODY and a cytotoxic immune cell (e.g., Cytokine-induced killer cell) to form Armed Activated CIK cells (ACCs), wherein the MSBODY comprising a first antigen binding moiety that has specificity for a tumor antigen, and a second antigen binding moiety that binds to the cell. Provided are also methods preparing a composition comprising a MSBODY and a cytotoxic immune cell, and methods for treating patients with CIK cells armed with bispecific antibodies.

Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell

The present invention provides a bispecific antibody. The bispecific antibody provided by the present invention comprises a single-chain unit and a monovalent unit, wherein the single-chain unit has a specific binding capability against surface antigen CD3 of an immune cell; the monovalent unit has a specific binding capability against the surface antigen EpCAM of a tumor cell; the single-chain unit comprises a single-chain variable fragment ScFv fused with an Fc fragment; and the monovalent unit comprises a light chain and heavy chain pair. The present invention also provides a preparation method of the bispecific antibody and pharmaceutical use of these antibodies.

Construction and application of bispecific antibody EpCAM&#xd7;CD3

Growing community of inventors

Wuhan, China

Lijuan Fang